Benitec Biopharma Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia

Reuters01-11

<a href="https://laohu8.com/S/BNTC">Benitec Biopharma</a> Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia

Benitec Biopharma Inc. has released a new presentation detailing the development of BB-301, a genetic medicine candidate for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia. BB-301 employs a single-vector approach that combines gene silencing of the mutant PABPN1 gene with the delivery of a functional, healthy gene. The therapy is administered directly to the pharyngeal constrictor muscles through intramuscular injection, aiming to restore normal muscle function by blocking the production of the harmful protein while supplying a new, functional version. The presentation highlights BB-301's clinical progress, including a 100% responder rate in Cohort 1 and ongoing pivotal study planning. The candidate has been granted Fast Track and Orphan Drug Designations from regulatory agencies. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief on January 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602531478?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-11 07:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602531478","market":"us","top_or_hot":-1,"title":"Benitec Biopharma Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BNTC\">Benitec Biopharma</a> Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BLT.AU\">Benitec Biopharma</a> Inc. has released a new presentation detailing the development of BB-301, a genetic medicine candidate for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia. BB-301 employs a single-vector approach that combines gene silencing of the mutant PABPN1 gene with the delivery of a functional, healthy gene. The therapy is administered directly to the pharyngeal constrictor muscles through intramuscular injection, aiming to restore normal muscle function by blocking the production of the harmful protein while supplying a new, functional version. The presentation highlights BB-301's clinical progress, including a 100% responder rate in Cohort 1 and ongoing pivotal study planning. The candidate has been granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and Orphan Drug Designations from regulatory agencies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief on January 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Benitec Biopharma Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBenitec Biopharma Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-11 07:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BNTC\">Benitec Biopharma</a> Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BLT.AU\">Benitec Biopharma</a> Inc. has released a new presentation detailing the development of BB-301, a genetic medicine candidate for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia. BB-301 employs a single-vector approach that combines gene silencing of the mutant PABPN1 gene with the delivery of a functional, healthy gene. The therapy is administered directly to the pharyngeal constrictor muscles through intramuscular injection, aiming to restore normal muscle function by blocking the production of the harmful protein while supplying a new, functional version. The presentation highlights BB-301's clinical progress, including a 100% responder rate in Cohort 1 and ongoing pivotal study planning. The candidate has been granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and Orphan Drug Designations from regulatory agencies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief on January 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTC","symbol_name":"Benitec Biopharma Limited","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260110:nNDL8Kgtlm:1","article_id":"2602531478","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602531478","pubTimestamp":1768089056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Benitec Biopharma Inc. has released a new presentation detailing the development of BB-301, a genetic medicine candidate for the treatment of Oculopharyngeal Muscular Dystrophy -related dysphagia. BB-301 employs a single-vector approach that combines gene silencing of the mutant PABPN1 gene with the delivery of a functional, healthy gene. The therapy is administered directly to the pharyngeal constrictor muscles through intramuscular injection, aiming to restore normal muscle function by blocking the production of the harmful protein while supplying a new, functional version. The presentation highlights BB-301's clinical progress, including a 100% responder rate in Cohort 1 and ongoing pivotal study planning. The candidate has been granted Fast Track and Orphan Drug Designations from regulatory agencies. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTC":"Benitec Biopharma Limited","BK4139":"生物科技"},"translate_title":"Benitec Biopharma公布针对OPMD相关吞咽困难的基因疗法突破","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTC":0.9},"content_text":"Benitec Biopharma Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia\n    \n\nBenitec Biopharma Inc. has released a new presentation detailing the development of BB-301, a genetic medicine candidate for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia. BB-301 employs a single-vector approach that combines gene silencing of the mutant PABPN1 gene with the delivery of a functional, healthy gene. The therapy is administered directly to the pharyngeal constrictor muscles through intramuscular injection, aiming to restore normal muscle function by blocking the production of the harmful protein while supplying a new, functional version. The presentation highlights BB-301's clinical progress, including a 100% responder rate in Cohort 1 and ongoing pivotal study planning. The candidate has been granted Fast Track and Orphan Drug Designations from regulatory agencies. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief on January 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602531478","isCrawlerRequest":true}